Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1.

2.

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.

Temraz S, Mukherji D, Shamseddine A.

Int J Mol Sci. 2015 Sep 23;16(9):22976-88. doi: 10.3390/ijms160922976. Review.

3.

BRAF as a target for cancer therapy.

Dienstmann R, Tabernero J.

Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. Review.

PMID:
21426297
4.

Resistance to MEK inhibitors: should we co-target upstream?

Poulikakos PI, Solit DB.

Sci Signal. 2011 Mar 29;4(166):pe16. doi: 10.1126/scisignal.2001948. Review.

PMID:
21447797
5.

[BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].

Zaleśna I, Hartman ML, Czyż M.

Postepy Hig Med Dosw (Online). 2016 May 9;70:471-88. Review. Polish.

6.

[Genetic factors predisposing to the development of papillary thyroid cancer].

Puzianowska-Kuźnicka M, Pietrzak M.

Endokrynol Pol. 2005 May-Jun;56(3):339-45. Review. Polish.

PMID:
16350729
7.

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

Rizzo D, Ruggiero A, Amato M, Maurizi P, Riccardi R.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1397-1405. Epub 2016 Aug 5. Review.

PMID:
27494648
8.
9.

Clinical experience of MEK inhibitors in cancer therapy.

Wang D, Boerner SA, Winkler JD, LoRusso PM.

Biochim Biophys Acta. 2007 Aug;1773(8):1248-55. Epub 2006 Nov 16. Review.

10.

Mouse models for BRAF-induced cancers.

Pritchard C, Carragher L, Aldridge V, Giblett S, Jin H, Foster C, Andreadi C, Kamata T.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1329-33. Review.

11.

New therapies for dedifferentiated papillary thyroid cancer.

Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, Benvenga S, Miccoli P, Antonelli A.

Int J Mol Sci. 2015 Mar 17;16(3):6153-82. doi: 10.3390/ijms16036153. Review.

12.

Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers.

Strohecker AM, White E.

Cancer Discov. 2014 Jul;4(7):766-72. doi: 10.1158/2159-8290.CD-14-0196. Epub 2014 May 23. Review.

13.

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.

Pratilas CA, Solit DB.

Clin Cancer Res. 2010 Jul 1;16(13):3329-34. doi: 10.1158/1078-0432.CCR-09-3064. Epub 2010 May 14. Review.

14.

Thyroid carcinoma: molecular pathways and therapeutic targets.

Nikiforov YE.

Mod Pathol. 2008 May;21 Suppl 2:S37-43. doi: 10.1038/modpathol.2008.10. Review.

15.

The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.

Pasqualetti G, Ricci S, Dardano A, Ferdeghini M, Del Tacca M, Monzani F.

Mini Rev Med Chem. 2011 Aug;11(9):746-52. Review.

PMID:
21707530
16.

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.

Penman CL, Faulkner C, Lowis SP, Kurian KM.

Front Oncol. 2015 Mar 3;5:54. doi: 10.3389/fonc.2015.00054. eCollection 2015. Review.

17.

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.

Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3. Review.

PMID:
28169047
18.

Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review.

Guerra A, Di Crescenzo V, Garzi A, Cinelli M, Carlomagno C, Tonacchera M, Zeppa P, Vitale M.

BMC Surg. 2013;13 Suppl 2:S44. doi: 10.1186/1471-2482-13-S2-S44. Epub 2013 Oct 8. Review.

19.

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.

Obaid NM, Bedard K, Huang WY.

Int J Mol Sci. 2017 Mar 8;18(3). pii: E585. doi: 10.3390/ijms18030585. Review.

Supplemental Content

Support Center